BHVN.N
Latest Trade
51.01USDChange
-0.34(-0.66%)Volume
139,429Today's Range
-
52.2052 Week Range
-
67.86As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 51.35 |
|---|---|
Open | 51.12 |
Volume | 139,429 |
3M AVG Volume | 13.85 |
Today's High | 52.20 |
Today's Low | 50.45 |
52 Week High | 67.86 |
52 Week Low | 29.17 |
Shares Out (MIL) | 52.24 |
Market Cap (MIL) | 2,682.52 |
Forward P/E | -5.48 |
Dividend (Yield %) | -- |
Biohaven's Troriluzole Advances Past Interim Futility Analysis In Phase 2/3 Alzheimer's Disease Study
Biohaven Posts Q3 Loss Of $2.04/Shr
Biohaven Pharmaceutical Gives Rimegepant FDA Mid Cycle Communication Update
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.
Industry
Biotechnology & Drugs
Executive Leadership
Thomas Lynch
Chairman of the Board
Vlad Coric
Chief Executive Officer, Director
James Engelhart
Chief Financial Officer, Treasurer
Kimberly A Gentile
Senior Vice President - Clinical Operations
Charles Conway
Chief Scientific Officer
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | -- |
Price To Book (MRQ) | 14.16 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 50.81 |
LT Debt To Equity (MRQ) | 50.81 |
Return on Investment (TTM) | -115.81 |
Return on Equity (TTM) | -106.70 |
Biohaven Pharmaceutical said on Friday it would continue testing its Alzheimer's disease treatment in a late-stage study as the drug had passed a so-called "futility analysis", sending shares up 4.1%.
Biohaven Pharmaceutical said on Friday it would continue with a late-stage study of its experimental Alzheimer's treatment on the recommendation of an independent data-monitoring committee based on an interim analysis of results.
Biohaven Pharmaceutical Holding Co Ltd said on Friday the U.S. health regulator failed to approve its treatment for amyotrophic lateral sclerosis, or Lou Gehrig's disease, sending its shares down nearly 6% in extended trading.
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its commercial viability as the efficacy data failed to distinguish from Allergan's rival treatment.
Biohaven Pharmaceutical Holding Co Ltd said its migraine treatment met the main goals in two late-stage studies but the efficacy data failed to differentiate when compared with rival treatments in a crowded field.
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd:
Biohaven Pharmaceutical Holding Company Ltd-
Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd
Biohaven Pharmaceutical Holding Company Ltd
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.